Pharma Articles - Insights & Trends | World Pharma Today

RABS upgrade for Inibsa, Achieving Annex 1 compliance together

Yuvraj — Thu, 08 Oct 2026 13:34:41 +0000

Compliance with EU GMP Annex 1 is one of the key challenges currently facing pharmaceutical manufacturers and CMOs. For Inibsa, a global leader in the dental market, this required upgrading its production facility with filling lines equipped with Restricted Access Barrier Systems. In collaboration with its long-standing partners Imco and Syntegon, Inibsa not only implemented […]

The post RABS upgrade for Inibsa, Achieving Annex 1 compliance together first appeared on World Pharma Today.

Milestone Leadership in Action: Behaviors That Build Winning Biotech Companies

Yuvraj — Thu, 08 Oct 2026 13:27:13 +0000

The biotech industry has never lacked brilliant scientists or bold ideas. What is often missing is leadership recognizing the behaviors required to build a great early-stage company are not the same as those required to take it to market — and willingness to adapt accordingly. In our recent report, From Science to Scale: Building Biotech […]

The post Milestone Leadership in Action: Behaviors That Build Winning Biotech Companies first appeared on World Pharma Today.

Beyond the Digital Foundation: How Connected Intelligence Is Redefining Pharma Production

Yuvraj — Tue, 06 Oct 2026 09:01:20 +0000

Over the past two decades partnering with pharmaceutical leaders, I have witnessed a profound revolution in how modern plants operate. Facilities poured capital into technological infrastructure to upgrade shop floors, secure regulatory compliance, and achieve transparency that once seemed unattainable. ERP software centralized enterprise planning, MES overhauled shop-floor execution, QMS locked down compliance standards, and […]

The post Beyond the Digital Foundation: How Connected Intelligence Is Redefining Pharma Production first appeared on World Pharma Today.

India’s ₹2,333 Crore Weight-Loss Drug Story: Mounjaro, Semaglutide and the Next Phase of Competition

Yuvraj — Mon, 05 Oct 2026 11:45:55 +0000

India’s weight-loss drug story has moved well beyond a niche pharmaceutical category. GLP-1 medicines are now creating a rapidly expanding business around obesity and metabolic health, with Mounjaro and semaglutide at the centre of the competition. India’s GLP-1 segment reached ₹2,333 crore in sales for the 12 months ended August 2026. Unit sales grew 74% […]

The post India’s ₹2,333 Crore Weight-Loss Drug Story: Mounjaro, Semaglutide and the Next Phase of Competition first appeared on World Pharma Today.

eschbach Launches New Digital Leader Standard Work Capability for Pharma Process Operations

Yuvraj — Mon, 05 Oct 2026 11:20:47 +0000

Seqonis Intelligent Operations by eschbach has a new dedicated capability called Leader Standard Work capability, which empowers pharmaceutical organizations to bring leadership routine planning, execution, documentation and evaluation into a single digital workflow. What does this mean for pharmaceutical manufacturers operating in highly regulated environments? Leadership activities can now be performed consistently as well as […]

The post eschbach Launches New Digital Leader Standard Work Capability for Pharma Process Operations first appeared on World Pharma Today.

Where nasal drug development goes wrong, and how to get ahead of it

Yuvraj — Sat, 03 Oct 2026 07:39:12 +0000

Nasal delivery is attracting interest for both systemic therapies and drugs targeting the central nervous system (CNS). The nasal mucosa offers a route to systemic absorption that avoids first-pass metabolism, while delivery via the olfactory and trigeminal pathways is being explored as a way to reach the CNS. But a promising molecule and formulation are […]

The post Where nasal drug development goes wrong, and how to get ahead of it first appeared on World Pharma Today.

Obesity Drugs 2.0: The Race for More Powerful, Convenient and Next-Generation Weight-Loss Medicines

Yuvraj — Sat, 19 Sep 2026 06:45:52 +0000

Obesity treatment is entering a more competitive phase. Ozempic and Mounjaro helped make GLP-1-based medicines mainstream, but the next wave is looking beyond simply producing weight loss. The opportunity is significant because obesity remains widespread. U.S. data show that 40.3% of adults had obesity in 2021–2023, while 9.7% had severe obesity. Towards Healthcare Research and […]

The post Obesity Drugs 2.0: The Race for More Powerful, Convenient and Next-Generation Weight-Loss Medicines first appeared on World Pharma Today.

Beyond Market Access: Operational Regulatory Readiness Has Become the Real Gateway to Europe’s Pharmaceutical Market

Yuvraj — Mon, 07 Sep 2026 13:01:56 +0000

Over the past two decades, the global pharmaceutical industry’s geography has changed profoundly: India’s pharmaceutical sector has evolved from a low-cost manufacturing base into a globally competitive industry capable of supplying regulated markets. China remains structurally critical, above all for APIs and key starting materials. South Korea is moving rapidly up the pharmaceutical value chain, […]

The post Beyond Market Access: Operational Regulatory Readiness Has Become the Real Gateway to Europe’s Pharmaceutical Market first appeared on World Pharma Today.

Why the fastest route to low-GWP pMDIs requires more than a new propellant

Yuvraj — Thu, 27 Aug 2026 10:02:56 +0000

Opinion by Darren Bromley-Davenport, Technical Manager at Orbia Fluor & Energy Materials The transition to low-global warming potential (GWP) pressurised metered-dose inhalers (pMDIs) is now well underway. In recent years, significant progress has been made in identifying alternative propellants capable of reducing the environmental impact of pMDIs while maintaining the performance patients rely on. Among […]

The post Why the fastest route to low-GWP pMDIs requires more than a new propellant first appeared on World Pharma Today.

Why More Data Doesn’t Automatically Mean Better AI in Drug Discovery

Yuvraj — Mon, 17 Aug 2026 07:18:26 +0000

When DeciBio asked nine senior pharma executives what was holding back AI adoption in R&D, the answer wasn’t algorithms or compute. Three of the top four barriers they named were data problems, and low-quality data was cited by every single one of them. Every AI drug discovery pitch deck has a slide about proprietary data. […]

The post Why More Data Doesn’t Automatically Mean Better AI in Drug Discovery first appeared on World Pharma Today.